Accepted author manuscript, 317 KB, PDF document
Available under license: CC BY: Creative Commons Attribution 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Cost-effectiveness of levodopa-carbidopa intestinal gel in treating people with advanced Parkinson's disease
AU - Raj, Sonia
AU - Sarvankar, Rekha
AU - Filipe, Luís
AU - Benedetto, Valerio
AU - Mason, Nicola
AU - Dawber, Jennifer
AU - Hill, James
AU - Clegg, Andrew
PY - 2023/8/2
Y1 - 2023/8/2
N2 - Advanced Parkinson's disease causes further deterioration in the physical and cognitive functions of patients with existing Parkinson's disease. This commentary critically assesses an economic evaluation which compared the cost-effectiveness of levodopa/carbidopa intestinal gel against standard of care in treating patients with advanced Parkinson's disease. While the economic evaluation indicated that levodopa/carbidopa intestinal gel could be cost-effective within the UK parameters, the authors of this commentary highlight important limitations related to its design, modelling and analysis. Future research should consider the incorporation of a separate arm dedicated to the re-infusion of apomorphine in eligible patients with advanced Parkinson's disease, a wider set of levodopa/carbidopa intestinal gel adverse events and related costs, and a sub-group analysis on different socioeconomic strata.
AB - Advanced Parkinson's disease causes further deterioration in the physical and cognitive functions of patients with existing Parkinson's disease. This commentary critically assesses an economic evaluation which compared the cost-effectiveness of levodopa/carbidopa intestinal gel against standard of care in treating patients with advanced Parkinson's disease. While the economic evaluation indicated that levodopa/carbidopa intestinal gel could be cost-effective within the UK parameters, the authors of this commentary highlight important limitations related to its design, modelling and analysis. Future research should consider the incorporation of a separate arm dedicated to the re-infusion of apomorphine in eligible patients with advanced Parkinson's disease, a wider set of levodopa/carbidopa intestinal gel adverse events and related costs, and a sub-group analysis on different socioeconomic strata.
KW - Neurology (clinical)
KW - General Nursing
U2 - 10.12968/bjnn.2023.19.4.140
DO - 10.12968/bjnn.2023.19.4.140
M3 - Journal article
VL - 19
SP - 140
EP - 144
JO - British Journal of Neuroscience Nursing
JF - British Journal of Neuroscience Nursing
SN - 1747-0307
IS - 4
ER -